"A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 3"
2022-06-27
عنوان الدراسة
"A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 3"
داعم الدراسة
Eli Lilly
دواء الدراسة
Mirikizumab
رقم بروتوكول الدراسة
I6T-MC-AMAP
حالة الدراسة
Completed
موقع الدراسة
King Fahad Specialist Hospital (Dammam)
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.